4657894 New factor VIII coagulant polypeptides
1
368 PATENT ABSTRACTS Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8UI myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed. 4657852 METHOD FOR B CELL TYPING OF TOTAL HUMAN LYMPHOCYTE SAMPLE Frank C Grumet, Edgar G Engleman assigned to The Board of Trustees of the Leland Stanford Junior University An HLA-DR typing test based on lympho- cytotoxicity in which a vital dye-labeled total human lymphocyte sample, such as a sample of peripheral blood lymphocytes, is incubated with HLA-DR antisera, a monoclonal antibody against T cells, and complement and the DR type is determined based upon the resultant cyto- toxicity as measured by the fluorescence of B cells surviving the incubation. according to the present invention, exhibits a higher producibility of immunoglobulin G and immunoglobulin M antibodies, while it induces less or substantially no production of immuno- globulin E antibody, in comparison with conventional-type inactivated virus vaccine; thus. the present vaccine is favorably usable for the prevention and treatment of viral diseases. 4659669 MICROBIAL EXPRESSION OF HUMAN INFLUENZA HEMAGGLUTININ PROTEINS Dennis Kleid, Debi P Nayak, Alan R Davis as- signed to Regents of the Univ of California; Genentech Inc Disclosed herein are methods and means for microbially expressing human influenza hemag- glutinin proteins, useful in the preparation of vaccines, by recombination of DNA gene sequences coding for hemagglutinin protein with microbially operable promoter-operator DNA and transformation of microbial host therewith. 4657894 NEW FACTOR VIII COAGULANT POLYPEPTIDES Theodore S Zimmerman, Carol A Fulcher as- signed to Scripps Clinic & Research Foundation Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed. 4659569 PROCESS FOR THE PRODUCTION OF VIRUS VACCINE Masakazu Mitsuhashi, Shunsaku Koyama, Okayama, Japan assigned to Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo The present invention relates to a process for the production of virus vaccine, comprising cova- lently attaching virus to saccharide to form a virus-saccharide conjugate, and harvesting the resultant conjugate. The virus vaccine, prepared 4659678 IMMUNOASSAY OF ANTIGENS Gordon Forrest, Philip R P Salacinski, Kenneth Siddle, lngatestone, United Kingdom assigned to Serono Diagnostics Limited A method of immunoassay of an antigen in a li- quid sample wherein a complex is formed bet- ween antigen contained in the said sample and two or more antibody reagents, and the said complex is bound to a solid support by non- covalent bonding as defined herein; and the amount of complex becoming bound to the sup- port is determined; the process employing at least one monoclonal antibody reagent. Label- ling methods including radio-active, fluorimetric and enzyme labelling may be used to effect deter- mination of the binding of the complex to the solid support. The solid support may take the form of particles, beads, wall-coatings on the reaction vessel or an insert of large surface area. The method is particularly applicable to the as- say of TSH, CEA, HCG, alphafeto protein, immunoglobulins, viruses, allergens, bacteria, toxins, drugs and vitamins. Use of monoclonal reagents improves the specificity of the process, and also decreases non-specific binding.
Transcript of 4657894 New factor VIII coagulant polypeptides
368 PATENT ABSTRACTS
Hybrid cell line for production of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8UI myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
4657852
M E T H O D F O R B C E L L T Y P I N G O F T O T A L H U M A N
L Y M P H O C Y T E S A M P L E
Frank C Grumet, Edgar G Engleman assigned to The Board of Trustees of the Leland Stanford Junior University
An HLA-DR typing test based on lympho- cytotoxicity in which a vital dye-labeled total human lymphocyte sample, such as a sample of peripheral blood lymphocytes, is incubated with HLA-DR antisera, a monoclonal antibody against T cells, and complement and the DR type is determined based upon the resultant cyto- toxicity as measured by the fluorescence of B cells surviving the incubation.
according to the present invention, exhibits a higher producibility of immunoglobulin G and immunoglobulin M antibodies, while it induces less or substantially no production of immuno- globulin E antibody, in comparison with conventional-type inactivated virus vaccine; thus. the present vaccine is favorably usable for the prevention and treatment of viral diseases.
4659669
M I C R O B I A L E X P R E S S I O N O F H U M A N I N F L U E N Z A
H E M A G G L U T I N I N P R O T E I N S
Dennis Kleid, Debi P Nayak, Alan R Davis as- signed to Regents of the Univ of California; Genentech Inc
Disclosed herein are methods and means for microbially expressing human influenza hemag- glutinin proteins, useful in the preparation of vaccines, by recombination of DNA gene sequences coding for hemagglutinin protein with microbially operable promoter-operator DNA and transformation of microbial host therewith.
4657894
N E W F A C T O R VII I C O A G U L A N T P O L Y P E P T I D E S
Theodore S Zimmerman, Carol A Fulcher as- signed to Scripps Clinic & Research Foundation
Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.
4659569
P R O C E S S F O R T H E P R O D U C T I O N O F V I R U S
V A C C I N E
Masakazu Mitsuhashi, Shunsaku Koyama, Okayama, Japan assigned to Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
The present invention relates to a process for the production of virus vaccine, comprising cova- lently attaching virus to saccharide to form a virus-saccharide conjugate, and harvesting the resultant conjugate. The virus vaccine, prepared
4659678
I M M U N O A S S A Y O F A N T I G E N S
Gordon Forrest, Philip R P Salacinski, Kenneth Siddle, lngatestone, United Kingdom assigned to Serono Diagnostics Limited
A method of immunoassay of an antigen in a li- quid sample wherein a complex is formed bet- ween antigen contained in the said sample and two or more antibody reagents, and the said complex is bound to a solid support by non- covalent bonding as defined herein; and the amount of complex becoming bound to the sup- port is determined; the process employing at least one monoclonal antibody reagent. Label- ling methods including radio-active, fluorimetric and enzyme labelling may be used to effect deter- mination of the binding of the complex to the solid support. The solid support may take the form of particles, beads, wall-coatings on the reaction vessel or an insert of large surface area. The method is particularly applicable to the as- say of TSH, CEA, HCG, alphafeto protein, immunoglobulins, viruses, allergens, bacteria, toxins, drugs and vitamins. Use of monoclonal reagents improves the specificity of the process, and also decreases non-specific binding.
